Hudson Bay Capital Management
ANTX icon

Hudson Bay Capital Management’s AN2 Therapeutics ANTX Stock Holding History

Hudson Bay Capital Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-34,605
Closed -$118K – 1358
2026
Q1 		$118K Buy
+34,605
New +$71.4K ﹤0.01% 1162

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Hudson Bay Capital Management's ANTX Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of AN2 Therapeutics (ANTX) in Q2 2026, closing a stake of 34,605 shares — an estimated $118K sold.

Hudson Bay Capital Management first reported a position in ANTX in Q1 2026 and held it in 1 quarter. The position peaked at $118K in Q1 2026. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining AN2 Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 34,605 AN2 Therapeutics shares in Q2 2026, an estimated $118K.
  • Hudson Bay Capital Management first reported a position in AN2 Therapeutics in Q1 2026 and held it in 1 quarter.
  • Hudson Bay Capital Management's AN2 Therapeutics position peaked at $118K in Q1 2026.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.